AIMS: Serum C-peptide can be used in Type 2 diabetes as a measure of endogenous insulin secretion, but practicalities of collection limit its routine clinical use. Urine C-peptide creatinine ratio is a non-invasive alternative that is stable for at least 3 days at room temperature in boric acid preservative. We aimed to assess the utility of urine C-peptide creatinine ratio in individuals with Type 2 diabetes as an alternative to serum C-peptide. METHODS: We assessed, in 77 individuals with Type 2 diabetes, the reproducibility of, and correlations between, fasting and postprandial urine C-peptide creatinine ratio and serum C-peptide, and the impact of renal impairment (estimated glomerular filtration rate < 60 ml min(-1) 1.73 m(-2)) on these correlations. RESULTS: Urine C-peptide creatinine ratio was at least as reproducible as serum C-peptide [fasting coefficient of variation mean (95% CI): 28 (21-35)% vs. 38 (26-59)% and 2-h post-meal 26 (18-33)% vs. 27 (20-34)%. Urine C-peptide creatinine ratio 2 h post-meal was correlated with stimulated serum C-peptide, both the 2-h value (r = 0.64, P < 0.001) and the 2-h area under the C-peptide curve (r = 0.63, P < 0.001). The association seen was similar in patients with and without moderate renal impairment (P = 0.6). CONCLUSIONS: In patients with Type 2 diabetes, a single urine C-peptide creatinine ratio is a stable, reproducible measure that is well correlated with serum C-peptide following meal stimulation, even if there is moderate renal impairment. Urine C-peptide creatinine ratio therefore has potential for use in clinical practice in the assessment of Type 2 diabetes.
AIMS: Serum C-peptide can be used in Type 2 diabetes as a measure of endogenous insulin secretion, but practicalities of collection limit its routine clinical use. Urine C-peptidecreatinine ratio is a non-invasive alternative that is stable for at least 3 days at room temperature in boric acid preservative. We aimed to assess the utility of urine C-peptidecreatinine ratio in individuals with Type 2 diabetes as an alternative to serum C-peptide. METHODS: We assessed, in 77 individuals with Type 2 diabetes, the reproducibility of, and correlations between, fasting and postprandial urine C-peptidecreatinine ratio and serum C-peptide, and the impact of renal impairment (estimated glomerular filtration rate < 60 ml min(-1) 1.73 m(-2)) on these correlations. RESULTS: Urine C-peptidecreatinine ratio was at least as reproducible as serum C-peptide [fasting coefficient of variation mean (95% CI): 28 (21-35)% vs. 38 (26-59)% and 2-h post-meal 26 (18-33)% vs. 27 (20-34)%. Urine C-peptidecreatinine ratio 2 h post-meal was correlated with stimulated serum C-peptide, both the 2-h value (r = 0.64, P < 0.001) and the 2-h area under the C-peptide curve (r = 0.63, P < 0.001). The association seen was similar in patients with and without moderate renal impairment (P = 0.6). CONCLUSIONS: In patients with Type 2 diabetes, a single urine C-peptidecreatinine ratio is a stable, reproducible measure that is well correlated with serum C-peptide following meal stimulation, even if there is moderate renal impairment. Urine C-peptidecreatinine ratio therefore has potential for use in clinical practice in the assessment of Type 2 diabetes.
Authors: Richard A Oram; Timothy J McDonald; Beverley M Shields; Michelle M Hudson; Maggie H Shepherd; Suzanne Hammersley; Ewan R Pearson; Andrew T Hattersley Journal: Diabetes Care Date: 2014-12-17 Impact factor: 19.112
Authors: Richard A Oram; Andrew Rawlingson; Beverley M Shields; Coralie Bingham; Rachel E J Besser; Tim J McDonald; Bridget A Knight; Andrew T Hattersley Journal: BMJ Open Date: 2013-12-18 Impact factor: 2.692
Authors: Suzy V Hope; Sophie Wienand-Barnett; Maggie Shepherd; Sophie M King; Charles Fox; Kamlesh Khunti; Richard A Oram; Bea A Knight; Andrew T Hattersley; Angus G Jones; Beverley M Shields Journal: Br J Gen Pract Date: 2016-04-14 Impact factor: 5.386
Authors: Sjaam Jainandunsing; J L Darcos Wattimena; Trinet Rietveld; Joram N I van Miert; Eric J G Sijbrands; Felix W M de Rooij Journal: Endocrine Date: 2015-11-02 Impact factor: 3.633